Bionexis Summary Report
KRAS Rewiring Run (LUAD / PAAD / COREAD)
1. System Context

Bionexis is a modular reasoning system designed to reconstruct biological structure without prior assumptions.

This report documents a KRAS-centered run across three tumor contexts (LUAD, PAAD, COREAD), using a four-node architecture:

Node-0 — Non-hierarchical search space definition
Node-1 — Evidence-based directional convergence
Node-2 — Structure-preserving hypothesis generation
Node-3 — Translation into actionable architecture

No step introduces external inference beyond its defined scope.

2. Node-0 — Search Space Definition

Node-0 establishes the KRAS system as a parallel, non-hierarchical space:

Signaling axes (RAF–MEK–ERK, PI3K–AKT–mTOR, RTK inputs)
Metabolic programs (glutamine rewiring, glycolysis, FAO, ROS)
Co-mutation modifiers (STK11, KEAP1, TP53, SMAD4, PIK3CA)

These dimensions are treated as independent search axes with:

no prioritization
no dependency ordering
no causal assumptions

→ Node-0 defines where to search, not what matters

3. Node-1 — Evidence Convergence

Node-1 compresses IC50 response data into directional structure
(KRAS-mut vs WT, median shift-based)

3.1 Direction Matrix (LUAD)
Axis	Direction
MEK	S
ERK	S
EGFR	R
FGFR	M
pan-HER	R
3.2 Axis Relevance (LUAD)
Tier 1 (dominant signals)
MEK (S)
EGFR (R)
pan-HER (R)
Tier 2 (supporting)
ERK (S)
Tier 3 (non-stable)
FGFR (M)
3.3 Interpretation Boundary

Node-1 outputs are strictly:

observational (IC50-based)
non-mechanistic
non-causal

→ This layer defines directionality, not explanation

4. Node-2 — Structural Hypothesis Architecture

Node-2 converts directional evidence into topological structure
without introducing new data.

4.1 Emergent Topology

A two-branch architecture is observed in KRAS-mut LUAD:

MAPK Effector Branch (Dependency)

MEK — primary sensitivity anchor (Tier 1)
ERK — secondary supporting residue (Tier 2)

RTK Compensation Branch (Resistance)

EGFR — resistance anchor (Tier 1)
pan-HER — cooperative co-anchor (Tier 1)

FGFR

mixed signal (Tier 3)
retained as divergent residue
4.2 Structural Properties
Asymmetry preserved
MEK ≠ ERK (non-equivalent roles)
Parallel architecture
MAPK and RTK operate as distinct branches
Open residue retained
FGFR not resolved into dependency or compensation
4.3 Interpretation Boundary
No new evidence introduced
No cross-tumor extrapolation
No mechanism asserted

→ Node-2 defines structure, not truth

5. Node-3 — Translation Layer

Node-3 converts structural topology into actionable architecture

5.1 Structural Translation
MAPK dependency
MEK-centered actionable node
RTK compensation
EGFR / pan-HER buffering architecture
FGFR divergence
conditional or subpopulation-dependent role
5.2 Structural Tension

MAPK dependency vs RTK compensation defines a system capable of:

signal persistence
pathway re-engagement
adaptive rebalancing
5.3 Boundary
No clinical claims
No therapeutic recommendations
Experimental validation required

→ Node-3 defines where intervention becomes testable

6. Validation

KRAS biology is well-characterized.

In this run:

No prior ranking was imposed (Node-0)
No mechanism was assumed (Node-1)
No external evidence was added (Node-2)

Yet the system converged to:

MAPK dependency (MEK-centered)
RTK-mediated resistance architecture
FGFR as unresolved context-dependent residue
Key Statement

Convergence without prior assumption = system validation

7. System Integrity

This run preserves strict separation between layers:

Node	Function	Constraint
N0	Search space	No ranking
N1	Evidence	No inference
N2	Structure	No new data
N3	Translation	No over-claim
Final Note

Bionexis does not discover KRAS biology.

It reconstructs it —
without being told what to find.
